SSSandra Pinho Silveiro

Sandra Pinho Silveiro

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sandra Pinho Silveiro has a total of 36 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Equation Pronouncedly Underestimates Glomerular Filtration Rate in Type 2 Diabetes

    by Sandra P. Silveiro, Gustavo N. Araújo, Mariana N. Ferreira, Fabíola D.S. Souza, Halley M. Yamaguchi, Eduardo G. Camargo

    OBJECTIVE: To evaluate the performance of the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation to estimate glomerular filtration rate (GFR) in type 2 diabetic patients with GFR >60 mL/min/1.73 m2. RESEARCH DESIGN AND METHODS: This was a cross-sectional study including 105 type 2 diabetic patients. GFR was measured by 51Cr-EDTA method and estimated by the MDRD and CKD-EPI equations. Serum creatinine was measured by the traceable Jaffe method. Bland-Altman plots were used. Bias, accuracy (P30), and precision were evaluated. RESULTS: The mean age of patients was 57 ± 8 years; 53 (50%) were men and 90 (86%) were white. Forty-six (44%) patients had microalbuminuria, and 14 (13%) had macroalbuminuria. 51Cr-EDTA GFR was 103 ± 23, CKD-EPI GFR was 83 ± 15, and MDRD-GFR was 78 ± 17 mL/min/1.73 m2 (P < 0.001). Accuracy (95% CI) was 67% (58–74) for CKD-EPI and 64% (56–75) for MDRD. Precision was 21 and 22, respectively. CONCLUSIONS: The CKD-EPI and MDRD equations pronouncedly underestimated GFR in type 2 diabetic patients.


  • The Chronic Kidney Disease Epidemiology Collaboration (CKD‐EPI) equation is less accurate in patients with Type 2 diabetes when compared with healthy individuals

    by E. G. Camargo, A. A. Soares, A. B. Detanico, L. S. Weinert, F. V. Veronese, E. C. Gomes, S. P. Silveiro

    Diabet. Med. 28, 90–95 (2011) Aims  To analyse the performances of Chronic Kidney Disease Epidemiology Collaboration (CKD‐EPI) and of Modification of Diet in Renal Disease (MDRD) study equations to estimate glomerular filtration rate (GFR) in patients with Type 2 diabetes mellitus with GFRs >60 ml/min and in healthy volunteers.Methods  This cross‐sectional study included 111 individuals (56 patients with Type 2 diabetes and 55 healthy volunteers), aged 58 ± 9 years; 54 individuals were men (49%) and ninety‐eight (88%) were white. Glomerular filtration rate was measured by the 51Cr‐EDTA single‐injection method (51Cr‐GFR) and estimated according to the standardized MDRD and CKD‐EPI equations. Serum creatinine was measured by a traceable Jaffe method. Bland–Altman analysis was used to examine the agreement between measured and estimated GFR. Bias, accuracy and precision were evaluated.Results  In diabetic individuals, 51Cr‐GFR was 106 ± 27 ml/min/1.73 m2, CKD‐EPI‐estimated GFR 82 ± 18 ml/min/1.73 m2 and MDRD‐estimated GFR 80 ± 21 ml/min/1.73 m2 (P < 0.001). In healthy volunteers, the corresponding values were 98 ± 20, 89 ± 13 and 84 ± 14 ml/min/1.73 m2 (P < 0.001). The accuracy of CKD‐EPI (P30) was higher in healthy volunteers than in diabetic patients (90 vs. 66%, respectively, P < 0.001). The MDRD equation performed as poorly as the CKD‐EPI equation in individuals with Type 2 diabetes.Conclusions  The CKD‐EPI equation is less accurate in patients with Type 2 diabetes when compared with healthy individuals, with a 2.5‐fold greater bias.


  • Glomerular filtration rate measurement and prediction equations

    by Ariana Aguiar Soares, Tatiana Falcão Eyff, Raquel Barth Campani, Luciana Ritter, Joíza Lins Camargo, Sandra Pinho Silveiro

    Chronic kidney disease (CKD) is defined as the presence of kidney damage or a glomerular filtration rate (GFR) <60 mL/min/1.73 m(2) for three or more months. Measurement of serum creatinine is the most commonly used method to evaluated kidney function, but it must be included in formulas to estimate GFR, adjusting for age, gender and ethnicity, such as the Modification of Diet in Renal Disease (MDRD) study equation. The performance of this equation is acceptable for patients with CKD but appears to under-estimate GFR in populations with unknown kidney status. A new formula has been developed recently. The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation appears to perform better than the MDRD equation. Cystatin C has been widely evaluated as a marker for GFR and seems to be more sensitive than creatinine. The aim of this review is to discuss the recommendations for detecting CKD, emphasizing the characteristics and limitations of GFR estimating equations and pitfalls in the evaluation of urinary albumin excretion.


  • Open Access

    HNF1α mutations are present in half of clinically defined MODY patients in South-Brazilian individuals

    by Jorge de Faria Maraschin, Caroline Kannengiesser, Nádia Murussi, Nicole Campagnolo, Luís Henrique Canani, Jorge Luiz Gross, Gilberto Velho, Bernard Grandchamp, Sandra Pinho Silveiro

    Maturity-onset diabetes of the young (MODY) is a monogenic form of diabetes mellitus characterized by autosomal dominant inheritance, early age of onset, and pancreatic beta cell dysfunction. Heterozygous mutations in at least seven genes can cause MODY. In the present study we investigated the relative prevalence of GCK (glucokinase) and HNF1α (hepatocyte nuclear factor 1α) mutations, the more frequent causes of MODY, in 13 South-Brazilian families with multiple cases of diabetes consistent with MODY. Heterozygous variants in GCK and HNF1α genes were observed respectively in one (7.7%), and six (46.2%) families. The six HNF1α variants are likely to cause diabetes in the families where they were observed. However, we could not ascertain whether the GCK Gly117Ser variant found in one family is a causal mutation. In conclusion, we have confirmed in a South-Brazilian population that HNF1α mutations are a common cause of monogenic diabetes in adults selected with strict clinical diagnostic criteria.


  • Open Access

    Detecção precoce da nefropatia diabética

    by Marcia Murussi, Nádia Murussi, Nicole Campagnolo, Sandra Pinho Silveiro

    Em virtude do prognóstico desfavorável das fases avançadas da nefropatia diabética (ND), o ideal é identificar o envolvimento renal de maneira precoce. A recomendação é a medida anual da excreção urinária de albumina (EUA), em amostras de urina casual, para detectar os estágios da ND [microalbuminúria (EUA 17-174 mg/l ou 30 a 300 mg albumina/g de creatinina) e macroalbuminúria (> 174 mg/l ou > 300 mg/g)]. No entanto, tem sido sugerido que níveis de EUA abaixo dos de consenso já seriam indicativos de risco de progressão renal e de mortalidade aumentada, devendo ser revisados esses pontos de corte. Uma quantidade expressiva da EUA, a fração não imunorreativa, não é detectada pelos métodos convencionais, e HPLC poderá ser mais sensível para identificar dano renal, medindo EUA total (imuno + não-imunorreativa). Outra observação recente é a presença de diminuição da taxa de filtração glomerular (TFG) mesmo em normoalbuminúricos. Portanto, além da EUA, recomenda-se estimar a TFG com equação empregando creatinina, como a do estudo Modification of Diet in Renal Disease (MDRD), disponível em www.mdrd.com. Em razão das conhecidas limitações da creatinina, marcadores endógenos alternativos estão em investigação, sendo a cistatina C um marcador promissor. Finalmente, novas estratégias que poderão ser ainda mais precoces para detecção da ND incluem biomarcadores, como proteoma, definindo um perfil de proteínas urinárias que identifiquem risco subseqüente de doença renal.


  • High‐normal levels of albuminuria predict the development of micro‐ and macroalbuminuria and increased mortality in Brazilian Type 2 diabetic patients: an 8‐year follow‐up study

    by M. Murussi, N. Campagnolo, M. O. Beck, J. L. Gross, S. P. Silveiro

    Aim  To analyse the risk factors for the development of micro‐ and macroalbuminuria and mortality rates in a cohort of normoalbuminuric Type 2 diabetes mellitus (DM) patients.Methods  In this prospective study, 193 Type 2 DM patients with urinary albumin excretion (UAE) < 20 µg/min, 96 men (50%), aged 56.5 ± 9 years, were followed for a mean period of 8 ± 3 years. UAE and estimated glomerular filtration rate (eGFR; Modification of Diet in Renal Disease) were measured. The outcomes were development of persistent micro‐ and macroalbuminuria and mortality.Results  Twenty patients were lost to follow‐up. Of the 173 remaining patients, 33 (19%) died. The Cox analysis [hazard ratio (HR), 95% confidence interval] revealed that the baseline significant predictors of mortality were higher UAE [above median (5 µg/min); HR 2.7, 1.2–6.1; P = 0.02], male sex (HR 3.9, 1.7–9.2; P = 0.002), age (HR 1.6, 1.3–1.9; P = 0.0001), and fasting plasma glucose (HR 1.2, 1.1–1.3; P = 0.004). Smoking and eGFR were not significant in this model. Follow‐up renal data were available for 158 patients: 34 (22%) progressed to microalbuminuria and seven (4%) to macroalbuminuria, and the baseline predictors were a higher UAE (> 5 µg/min, HR 2.5, 1.2–5.1; P = 0.02), presence of diabetic retinopathy (HR 2.5, 1.3–5.0; P = 0.009), fasting glucose (HR 1.1, 1.0–1.2; P = 0.015), and male sex (HR 2.2, 1.1–4.7; P = 0.04), independently of smoking and hypertension. Lower GFR (HR 0.98, 0.97–1.00; P = 0.07) was of borderline significance.Conclusions  In normoalbuminuric Type 2 DM patients, the development of micro‐ or macroalbuminuria and mortality rates was independently and positively associated with higher levels of albuminuria, although still in the traditionally established normal range.


  • Open Access

    Aspirina em baixa dosagem em pacientes com diabete melito: riscos e benefícios em relação às complicações macro e microvasculares

    by Eduardo G. Camargo, Jorge Luiz Gross, Letícia S. Weinert, Joel Lavinsky, Sandra P. Silveiro

    O uso de aspirina é recomendado como estratégia de prevenção cardiovascular em pacientes com diabete melito. Em decorrência do risco de eventos hemorrágicos e da hipótese de que poderia haver um agravamento das complicações microvasculares associado ao uso da aspirina, tem havido importante sub-utilização dessa terapia. Entretanto, está definido que o uso de aspirina não piora a retinopatia diabética e existem evidências de que também não afeta a função renal em doses usuais (150 mg/dia). Por outro lado, pacientes com diabete melito parecem necessitar de doses maiores do agente antiplaquetário, o que sugere que esses indivíduos apresentem a chamada "resistência à aspirina". Os mecanismos dessa resistência ainda não estão completamente esclarecidos, estando provavelmente relacionados à atividade plaquetária intrínseca anormal. Portanto, o emprego de terapêuticas antiplaquetárias alternativas ou a administração de doses maiores de aspirina (150-300 mg/dia) devem ser melhor avaliados em relação a um aumento da eficácia na prevenção da doença cardiovascular e também a possíveis efeitos nas complicações microvasculares no diabete melito.


  • Open Access

    Diabetic nephropathy in type 2 diabetes mellitus: risk factors and prevention

    by Marcia Murussi, Ariane Coester, Jorge Luiz Gross, Sandra Pinho Silveiro

    Diabetic nephropathy (DN) is responsible for the increasing number of patients on dialysis in developing countries, and is already the most common cause of renal replacement therapy in the developed ones. In this manuscript, we review the risk factors and point out strategies to prevent this microvascular complication in type 2 diabetic patients (DM2). There are some known genetic and non-genetic risk factors related to the development and progression of DN in DM2 patients. Candidate genes have been analysed, but there are still controversy about the genetic markers of the disease. Recognized non-genetic risk factors are poor glycemic, pressoric and lipidic control. Additionally, it has been suggested that the presence of diabetic retinopathy, autonomic neuropathy, smoking habit, higher protein ingestion, and higher normal levels of albuminuria (even within the normal range) are associated with an increased risk of developing DN. Some strategies have been investigated and proved to prevent or at least to postpone DN, such as to control blood pressure, glycemic levels and dyslipidemia. Furthermore, angiotensin-converting enzyme inhibitors and angiotensin-II blockers have independent effects, not explained by blood pressure control alone. Other therapeutic items are to consume a low protein diet and to quit smoking.